Chapter 6 The role of fluoro-deoxy glucose (FDG) positron emission tomography (PET) in the management of differentiated thyroid cancer

作者: Richard J. Robbins , Chee-Yeung Chan , R. Michael Tuttle , Steven M. Larson

DOI: 10.1016/S1569-2566(04)04006-2

关键词: Thyroid carcinomaPositron emission tomographyDiseaseFDG-Positron Emission TomographySymporterPathologyMedicineThyroid cancerPathologicalIodine

摘要: Publisher Summary This chapter describes the role of fluoro-deoxy glucose (FDG) positron emission tomography (PET) in management differentiated thyroid cancer. More than 70% deaths occur individuals whose initial histology is well-differentiated carcinoma. The current prognostic scoring systems, which utilize clinical and pathological information obtained at time diagnosis, have been very useful. major limitation their inability to predict outcome patients when, years later, they are discovered harbor metastases. particularly important as it well known that there a highly variable trajectory disease such patients. use FDG-PET scanning for evaluating with DTC has added understanding this protean disease. Metastatic lesions contain predominantly clones functional sodium–iodide symporter (NIS) transport radioactive iodine (RAI). less cannot effectively trap but much higher metabolic activity high FDG-avidity. Sensitivity RAI therapy also explained chapter.

参考文章(41)
Jerry M. Shuck, Lee P. Adler, Allen D. Bloom, Determination of malignancy of thyroid nodules with positron emission tomography. Surgery. ,vol. 114, pp. 728- 735 ,(1993)
June-Key Chung, Young So, Jae Sung Lee, Chang Woon Choi, Sang Moo Lim, Dong Soo Lee, Sung Woon Hong, Yeo Kyu Youn, Myung Chul Lee, Bo Youn Cho, None, Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan. The Journal of Nuclear Medicine. ,vol. 40, pp. 986- 992 ,(1999)
Nicolas Meeùs, Malou M-Louise Haine, Van Damme A. P. Mardaga. pp. 416- 417 ,(1986)
Heikki Joensuu, Aapo Ahonen, Imaging of Metastases of Thyroid Carcinoma with Fluorine-18 Fluorodeoxyglucose The Journal of Nuclear Medicine. ,vol. 28, pp. 910- 914 ,(1987)
Ulrich Feine, Wolfgang Müller-Schauenburg, Helmut Wöhrle, Jürgen Held, Jacek-P. Hanke, Roland Lietzenmayer, Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer The Journal of Nuclear Medicine. ,vol. 37, pp. 1468- 1472 ,(1996)
Yoshiharu Yonekura, Katsuya Sugimoto, Toshio Ohtsubo, Hidemasa Uematsu, Gota Tsuda, Hitoshi Saito, Kazutaka Yamamoto, Tatsuro Tsuchida, Yasushi Ishii, Atsuo Waki, Norihiro Sadato, Nobushige Hayashi, Nono Takahashi, Satoshi Nakamura, Fluorine-18-fluorodeoxyglucose PET versus thallium-201 scintigraphy evaluation of thyroid tumors. The Journal of Nuclear Medicine. ,vol. 39, pp. 453- 459 ,(1998)
Weiping Wang, Steven M. Larson, R. Michael Tuttle, Hovanes Kalaigian, Katherine Kolbert, Martin Sonenberg, Richard J. Robbins, Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine. Thyroid. ,vol. 11, pp. 1169- 1175 ,(2001) , 10.1089/10507250152741028
Mark S. Cohen, Nuri Arslan, Farrokh Dehdashti, Gerard M. Doherty, Terry C. Lairmore, L.Michael Brunt, Jeffrey F. Moley, Risk of malignancy in thyroid incidentalomas identified by fluorodeoxyglucose-positron emission tomography. Surgery. ,vol. 130, pp. 941- 946 ,(2001) , 10.1067/MSY.2001.118265
P. Lind, E. Kresnik, Gerhild Kumnig, H.-J. Gallowitsch, Isabel Igerc, Sabine Matschnig, Iris Gomez, 18F-FDG-PET in the follow-up of thyroid cancer. Acta Medica Austriaca. ,vol. 30, pp. 17- 21 ,(2003) , 10.1046/J.1563-2571.2003.02046.X
Weiping Wang, Homer Macapinlac, Steven M. Larson, Samuel D. J. Yeh, Timothy Akhurst, Ronald D. Finn, Juan Rosai, Richard J. Robbins, [18F]-2-Fluoro-2-Deoxy-d-Glucose Positron Emission Tomography Localizes Residual Thyroid Cancer in Patients with Negative Diagnostic 131I Whole Body Scans and Elevated Serum Thyroglobulin Levels The Journal of Clinical Endocrinology and Metabolism. ,vol. 84, pp. 2291- 2302 ,(1999) , 10.1210/JCEM.84.7.5827